Home / Business and Economy / Blackstone Sells 9.5% Stake in Mphasis in $800M Block Deal Spree
Blackstone Sells 9.5% Stake in Mphasis in $800M Block Deal Spree
18 Nov
Summary
- Blackstone to sell 9.5% stake in Mphasis at ₹2,570 per share
- Paytm, Emcure Pharma also see major stake sales by promoters, PE firms
- Block deals worth nearly ₹6,800 crore expected on Dalal Street
On November 18, 2025, Dalal Street is expected to witness a flurry of block deals worth nearly ₹6,800 crore ($800 million) as promoters and private equity firms look to cash out following the conclusion of the earnings season.
The biggest deal is set to be Blackstone's sale of up to a 9.5% stake in Mphasis, the IT services firm. Blackstone's promoter entity, BCP Topco IX Pte. Ltd., will sell the shares at a floor price of ₹2,570 per share, a 4.4% discount to the previous day's closing price. This transaction is expected to fetch around ₹4,626 crore.
Paytm is also seeing stake sales, with Saif III Mauritius, SAIF Partners, and Elevation Capital likely to offload up to 2% of the company's equity worth ₹1,640 crore. The floor price for this deal has been set at ₹1,281 per share, a 3.9% discount.
Additionally, Bain Capital is expected to sell up to 2% of Emcure Pharma's equity, worth up to ₹493 crore, at a floor price of ₹1,296.5 per share, a 7% discount.
These block deals come as a testament to the recovery seen in the shares of these companies, with Paytm and Emcure Pharma trading above their respective IPO prices. However, Mphasis remains a key focus, as Blackstone looks to partially cash out of its investment in the IT services firm.
